Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2016
At a glance
- Drugs RG 4733 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 May 2016 Time frame for primary endpoints changed.
- 06 May 2016 Status changed from active, no longer recruiting to discontinued as it was administratively completed.
- 23 Sep 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.